A panel of experts on Thursday recommended approval for the health minister to authorize the production and sale of two novel regenerative medical products utilizing induced pluripotent stem (iPS) cells. If approved, these products are anticipated to be the first of their kind globally.
Breakthrough Therapies Under Consideration
The products under review are cardiomyocyte patches designed for patients with heart disease and dopaminergic neurons intended for individuals suffering from Parkinson’s disease. The cardiomyocyte patches were developed by Cuorips, a company stemming from the University of Osaka, while Sumitomo Pharma created the dopaminergic neurons.
The panel’s approval comes under a conditional system, meaning that even with the minister’s approval, data collection on the products will continue for up to seven years. This ongoing monitoring is crucial, as ensuring the long-term safety of iPS cell-based therapies has been a significant challenge.
Testing and Results
Between 2018 and 2023, Kyoto University Hospital and other institutions tested the dopaminergic neurons on patients in their 50s and 60s. Approximately 5 million to 10 million neural cells were transplanted into the brain center of each patient. After a two-year observation period, four of the six patients involved demonstrated improvements in motor function. No serious side effects were reported, and the neurons appeared particularly effective in younger patients with milder symptoms.
The cardiomyocyte patches, measuring 4 to 5 centimeters in diameter and 0.1 millimeters in thickness, were tested on eight patients by 2023. Researchers confirmed both their safety and efficacy.
iPS cells are created using cells sourced from patients themselves or others, a process intended to minimize the risk of rejection.
Frequently Asked Questions
What types of diseases are these products intended to treat?
The products are intended to treat heart disease and Parkinson’s disease.
How many patients were involved in testing the cardiomyocyte patches?
The cardiomyocyte patches were tested on eight patients by 2023.
What was the timeframe for testing the dopaminergic neurons?
The dopaminergic neurons were tested on patients between 2018 and 2023.
What impact might these therapies have on the future of regenerative medicine?
Keep reading